



FOR IMMEDIATE RELEASE

Glysure Ltd. and Technomark Life Sciences Sign Partnership Agreement for Clinical Trials of Continuous Glucose Monitor.

Oxford, UK and Durham, NC USA/London, UK – January 25, 2010 – Glysure Limited and Technomark Life Sciences announced today that they have entered into an agreement for Technomark to lead the initial clinical assessment and validation of Glysure’s continuous glucose monitoring system. Glysure and Technomark will conduct a pilot clinical study to determine the accuracy, longevity and performance of the system in the Intensive Care Unit environment.

“We have followed Glysure for over a year, and are excited to work with them on progressing the development of their continuous glucose monitoring system,” said Allen Hakimi, Managing Director of Technomark Life Sciences. “This device addresses a very significant market need in a very elegant and easy to use manner and provides the ideal opportunity to expand our clinical development expertise into the medical device arena. Combined with the experienced Glysure management team, we look to move forward very quickly with the clinical proof of concept of the product.”

“We are very pleased to work with Technomark on the clinical development of our lead product,” said Chris Jones, CEO of Glysure. “Technomark’s clinical and regulatory capabilities have allowed us to move forward rapidly and accelerate our development timelines. We look forward to working with Technomark through the development and commercialization of our lead product.”

About Technomark Life Sciences:

Technomark Life Sciences is a specialty life sciences firm with a worldwide reputation for excellence spanning over two decades. With offices in Research Triangle Park (NC-USA), London (UK), Mumbai (India), and Nanjing (China), the Company specializes in product development, regional licensing and partnering, and CRO/CMO corporate growth. As follow-on to its first venture capital fund in 2002, in 2009 Technomark began its co-development/co-funding business model and is actively seeking opportunities for investment. For more information please visit www.technomarkls.com.

About Glysure Limited:

GlySure Ltd., is developing a continuous intravascular glucose monitoring system to meet the worldwide demand for implementation of Tight Glycemic Control / Intensive Insulin Therapy. The system uses a proprietary reversible fluorescent chemistry that allows real-time, continuous monitoring of blood glucose levels in situ.

Diana Cocora
Office Manager
Glysure Ltd
dcocora@glysure.com
+44 (0) 1235 858 264

Allen Hakimi
Managing Director
Technomark Life Sciences
+1 919 656 3624
+44 (0) 751 323 8920
ahakimi@technomarkls.com